Aditxt: Christopher Mitton

Aditxt, life sciences company developing technologies to improve immune system health through reprogramming and monitoring, said that it has appointed Christopher Mitton as president of the company's Pearsanta precision health subsidiary. Mitton continues to serve as CEO of MDNA Life Sciences, which sold its Mitomic blood-based early disease and cancer detection platform to Pearsanta in January. Prior to this he headed sales at Cancer Genetics. He also led the North American commercial expansion for French molecular diagnostics company Ipsogen, and subsequently managed the personalized healthcare portfolio at Qiagen, which acquired Ipsogen in 2011. Earlier in his career, Mitton held sales positions with BioChem Immunosystems, Abbott Diagnostics, and Bayer Healthcare. He holds a BS in molecular biology from Florida A&M University.